Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1455 • ACR Convergence 2023
Risk Factors of Cytomegalovirus Reactivation and Disease in Patients with Systemic Lupus Erythematosus
Miyu Wakatsuki¹, Hiroyuki Yamashita¹, Yuuya Akiyama¹, Setsuko Oyama¹, Shintarou Aozaki¹, Ryo Kuwata², Misa Yamaji¹, Takuya Harada¹, Kyouko Motomura¹, Yuusuke Nakamichi¹ and Hiroshi Kaneko³, ¹National Center for Global Health and Medicine, Tokyo, Japan, ²Department of Rheumatology, National Center for Global Health and Medicine, Tokyo, Japan, ³Division of Rheumatic Disease, National Center for Global Health and Medicine, Tokyo, Japan
Background/Purpose: Cytomegalovirus (CMV) infection is classified as an opportunistic infection that occurs in autoimmune diseases. Systemic lupus erythematosus (SLE) is one of the most frequently…
Abstract Number: 1472 • ACR Convergence 2023
Prevalence of Hepatic Injury in Patients with Systemic Lupus Erythematosus: A 28-Year Single Center Experience
Asif Hitawala¹, Zerai Manna², Yenealem Temesgen-Oyelakin³, Elaine Poncio³, Christopher Koh⁴, sarfaraz Hasni² and Theo Heller⁴, ¹NIDDK/NIH, Bethesda, MD, ²Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁴NIDDK/Liver disease branch, Bethesda, MD
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are known to have hepatic injury (HI), however large-scale longitudinal studies are lacking.We report our experience of HI…
Abstract Number: 1489 • ACR Convergence 2023
Treatment with Upadacitinib in Patients with Systemic Lupus Erythematosus Results in the Inhibition of B-Cell–related Biomarkers: Analysis of the M19-130 (SLEek) Phase 2 Study
Marie-Claude Gaudreau¹, James Fann¹, Alan Friedman¹, Thierry Sornasse¹ and Joan Merrill², ¹AbbVie, Inc., North Chicago, IL, ²Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: B-cell hyperactivity (1) is a hallmark of the disordered immunity of SLE, arising in the context of a complex array of innate and adaptive…
Abstract Number: 1507 • ACR Convergence 2023
Pharmacodynamic Changes in SLE Relevant Gene Expression Induced by Deucravacitinib in Patients Enrolled in the Phase 2 PAISLEY Trial
Chun Wu¹, Cristina Arriens², J. Michelle Kahlenberg³, Yanhua Hu¹, Coburn Hobar¹, Adrian Coles⁴ and Ian M. Catlett⁵, ¹Bristol Myers Squibb, Princeton, NJ, ²Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK, ³University of Michigan, Ann Arbor, MI, ⁴Bristol Myers Squibb, Lawrenceville, NJ, ⁵Bristol Myers Squibb, Pennington, NJ
Background/Purpose: Deucravacitinib (DEUC) is a first-in-class, oral, selective, allosteric inhibitor of TYK2. TYK2 is required for signal transduction downstream of cytokines implicated in SLE pathophysiology,…
Abstract Number: 1607 • ACR Convergence 2023
Autoantibodies to Transcription Factor a Mitochondria Link Mitochondrial Damage and Thrombosis in Systemic Lupus Erythematosus
Eduardo Gomez-Banuelos¹, Alessandra Ida Celia², Maria Isabel Trejo Zambrano³, Merlin Paz³, Erika Darrah³, Daniel Goldman⁴, Michelle Petri⁴ and Felipe Andrade³, ¹The Johns Hopkins University, Baltimore, MD, ²John Hopkins University of Medicine, Rome, Italy, ³Johns Hopkins University, Baltimore, MD, ⁴Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Upon activation with interferon (IFN) and RNP-immune complexes, defective mitophagy in neutrophils results in the release of mtDNA in complex with transcription factor A…
Abstract Number: 1834 • ACR Convergence 2023
Evaluation of Fibromyalgia, Clinical/Serologic Activity, and Patient Reported Outcomes in a Racially/Ethnically Diverse SLE Patient Cohort
Kelly Corbitt¹, Philip Carlucci², Brooke Cohen³, Mala Masson³, H Michael Belmont⁴, Amit Saxena⁵, Chung-E Tseng³, Jing Wang³, Kamil Barbour⁶, Jill Buyon⁷, Peter Izmirly² and Heather Gold³, ¹New York University, El Portal, FL, ²New York University School of Medicine, New York, NY, ³New York University, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵New York University Grossman School of Medicine, Rheumatology, New York, NY, ⁶Centers for Disease Control and Prevention, Atlanta, GA, ⁷NYU Grossman School of Medicine, New York, NY
Background/Purpose: SLE patients have a higher prevalence of fibromyalgia (FM) than the general population. FM symptoms, such as nociplastic pain and fatigue, are known to…
Abstract Number: 2105 • ACR Convergence 2023
Cohort-wide Immuno-phenotype Deconvolute Immunological and Clinical Heterogeneity Across Autoimmune Rheumatic Diseases
Hiroaki Tanaka¹, Yukinori Okada², Shingo Nakayamada¹, Yusuke Miyazaki³, Kyuto Sonehara⁴, Shinichi Namba⁵, Suguru Honda⁶, Yuya Shirai⁷, Kenichi Yamamoto⁵, Katsunori Ikari⁸, Masayoshi Harigai⁹, KOSHIRO SONOMOTO¹⁰ and Yoshiya Tanaka¹, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²University of Tokyo / Osaka University / RIKEN, Tokyo, Japan, ³The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kiakyusyu Fukuoka, Japan, ⁴University of Tokyo, Tokyo, Japan, ⁵Osaka University, Osaka, Japan, ⁶Tokyo Women's Medical University, Tokyo, Japan, ⁷Osaka University, Suita, Japan, ⁸Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ⁹Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ¹⁰University of Occupational and Environmental Health, Beppu, Japan
Background/Purpose: Autoimmune rheumatic diseases (AIRDs) are systemic but heterogeneous diseases characterized by orchestration of disrupted self-tolerance of immune systems. We face a challenge in characterizing…
Abstract Number: 2271 • ACR Convergence 2023
Longitudinal Changes in Type 1 & Type 2 SLE Activity
Amanda Eudy¹, Jennifer Rogers², Daniel Wojdyla³, Kai Sun², Rebecca Sadun², Mithu Maheswaranathan⁴, Jayanth Doss², Lisa Criscione-Schreiber⁴ and Megan Clowse⁵, ¹Duke University, Raleigh, NC, ²Duke University, Durham, NC, ³Duke Clinical Research Institute, Durham, NC, ⁴Duke University School of Medicine, Durham, NC, ⁵Duke University, Chapel Hill, NC
Background/Purpose: The Type 1 & 2 SLE Model encompass symptoms classically attributed to inflammation, including arthritis, rash, serositis and nephritis (Type 1 SLE), and symptoms…
Abstract Number: 2288 • ACR Convergence 2023
Scoping Literature Review and Focus Groups Interviews to Identify Candidate Domains for the SLE OMERACT Core Domain Set
Wils Nielsen¹, Vibeke Strand², Lee Simon³, Maya Desai⁴, Ioannis Parodis⁵, Alfred Kim⁶, Daniel Wallace⁷, Yashaar Chaichian⁸, Sandra Navarra⁹, Cynthia Aranow¹⁰, Meggan MacKay¹⁰, Kimberly Trotter¹¹, Oshrat Tayer-Shifman¹², Ali Duarte-Garcia¹³, Lai-Shan Tam¹⁴, Manuel Ugarte-Gil¹⁵, Guillermo Pons-Estel¹⁶, John Reynolds¹⁷, Mandana Nikpour¹⁸, Danae Papachristos¹⁹, Alberta Hoi²⁰, Alison Hendry²¹, Juanita Romero-Diaz²², Rosalind Ramsey-Goldman²³, Hanan Alrayes²⁴, Ibrahim Almaghlouth²⁵, Aarabi Thayaparan²⁶, Carolina Munoz-Grajales²⁷, Aaron Howe²⁸, Behdin Nowrouzi-Kia²⁸, Melanie Anderson²⁹, Dennisse Bonilla²⁹, Julian Thumboo³⁰, Marta Mosca³¹, Martin Aringer³², Sindhu Johnson³³, Aaron Drucker³⁴, Eric Morand³⁵, Ian Bruce³⁶ and Zahi Touma²⁸, ¹University of Toronto, Markham, ON, Canada, ²Stanford University, Portola Valley, CA, ³SDG LLC, West Newton, MA, ⁴OCAD University, Toronto, ON, Canada, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶Washington University School of Medicine, St. Louis, MO, ⁷Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁸Stanford University, San Mateo, CA, ⁹University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, ¹⁰Feinstein Institutes for Medical Research, Manhasset, NY, ¹¹University of Chicago, Chicago, IL, ¹²Meir Medical Center, Raanana, Israel, ¹³Mayo Clinic, Rochester, MN, ¹⁴The Chinese University of Hong Kong, New Territories, China, ¹⁵Universidad Cientifica del Sur, Lima, Peru, ¹⁶RELESSAR, Rosario, Argentina, ¹⁷University of Birmingham, Birmingham, United Kingdom, ¹⁸The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia, ¹⁹Mater Hospital, Brisbane, Australia, ²⁰Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Melbourne, Australia, ²¹Te Whatu Ora, Counties Manukau District, Middlemore Hospital, Auckland, New Zealand, ²²Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ²³Northwestern University, Chicago, IL, ²⁴Riyadh Military - Prince Soltan Military Medical City ( PSMMC ) - Olaya, Riyadh, Saudi Arabia, ²⁵King Saud University, Riyadh, Saudi Arabia, ²⁶Schroeder Arthritis Institute, Krembil Research Institute, Markham, ON, Canada, ²⁷UHN/TWH, Toronto, ON, Canada, ²⁸University of Toronto, Toronto, ON, Canada, ²⁹University Health Network, Toronto, ON, Canada, ³⁰Singapore General Hospital; Duke-NUS Medical School, Singapore, Singapore, ³¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ³²Faculty of Medicine TU Dresden, Dresden, Germany, ³³Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, ³⁴Women's College Hospital, Toronto, ON, Canada, ³⁵Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ³⁶University of Manchester, Manchester, United Kingdom
Background/Purpose: We established the OMERACT SLE Working Group in 2021 which includes over 150 members representing over 25 countries and 5 continents to develop a…
Abstract Number: 2305 • ACR Convergence 2023
Infection Vulnerability in Pregnant Women with and Without Systemic Lupus Erythematosus
Dr Hiba Khogali¹, Ghada Al‐Bluwi², Virgie Guy² and Ali Al Dhanhani³, ¹Tawam Hospital, Al Ain, United Arab Emirates, ²College of Medicine, UAE University, Al Ain, United Arab Emirates, ³UAE University, Al Ain, United Arab Emirates
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that predominantly affects women of childbearing age. Pregnant women with SLE have higher rates of…
Abstract Number: 2321 • ACR Convergence 2023
Does the Perspective of SLE Patients Match the Expert Opinion and Definitions of Remission and Low Disease Activity State? Prospective Analysis of 500 Patients from a Spanish Multicenter Cohort
CORAL Mourino Rodriguez¹, Jose-Maria Pego-Reigosa², Iñigo Rúa-Figueroa³, Francisco Rubino⁴, Iñigo Hernández-Rodríguez⁵, Raúl Menor-Almagro⁶, Esther Uriarte Isacelaya⁷, Eva Tomero Muriel⁸, TAREK CARLOS SALMAN MONTE⁹, MARIA IRENE CARRION BARBERA⁹, Maria Galindo¹⁰, Esther Rodriguez almaraz¹⁰, Norman Jiménez¹¹, Luis Ines¹² and Irene Altabas Gonzalez¹³, ¹Complejo Hospitalario Universitario de Vigo. IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain, ²Rheumatology, Hospital do Meixoeiro, Vigo, Spain, ³Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ⁴Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain, ⁵Hospital do Meixoeiro. Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁶Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, ⁷Hospital Universitario de Donostia, Donostia, Spain, ⁸Rheumatology, Hospital La Princesa, Madrid, Spain, ⁹Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ¹⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ¹¹IIRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute., Vigo, Spain, ¹²Centro Hospitalar e Universitario de Coímbra, Coimbra, Portugal, ¹³Complejo Hospitalario Universitario de Vigo, IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain
Background/Purpose: There is no information available regarding whether the patient's perception of disease activity aligns with current definitions of DORIS 2021 remission and Lupus Low…
Abstract Number: 2340 • ACR Convergence 2023
Multi-targeted Therapy Better in Achieving Complete Response in Lupus Nephritis: A Systematic Review and Meta-analysis
Omer Pamuk¹, Bisma Shaikh², Saif Khan³, Ali Abbas⁴, Sarah Abi Doumeth⁵ and sarfaraz Hasni⁶, ¹University Hospitals Cleveland Medical Center, Cleveland, OH, ²Jinnah Sindh Medical University, Karachi, Pakistan, ³College of Medical and Dental Sciences, Birmingham, United Kingdom, ⁴Alabama College of Osteopathic Medicine, Dothan, AL, ⁵Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, ⁶Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: The overall management of SLE and Lupus Nephritis (LN) has significantly improved over the last four decades.Recently great therapeutic strides have been made in…
Abstract Number: 2447 • ACR Convergence 2023
Interleukin-6 Activates Glial Cells and Induces Cognitive Dysfunction in Murine Neuropsychiatric Lupus
Joshua Reynolds¹, Michelle Huang¹, Myriam Meineck², Tamara Möckel², Andreas Schwarting² and Chaim Putterman¹, ¹Albert Einstein College of Medicine, Bronx, NY, ²University Medical Center of the Johannes Gutenberg University of Mainz, Mainz, Germany
Background/Purpose: Up to 50% of SLE patients experience neuropsychiatric involvement (neuropsychiatric lupus, or NPLSE) in the form of cognitive deficits, memory loss, depression, and anxiety.…
Abstract Number: 2502 • ACR Convergence 2023
Self-Reported Sleep Disorders Among Individuals with Systemic Lupus Erythematosus
Patti Katz¹, Maria Dall'Era², Jinoos Yazdany³ and Kaleb Michaud⁴, ¹University of California San Francisco, San Rafael, CA, ²University of California San Francisco, San Francisco, CA, ³University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Research in the general population has linked sleep disorders to poor outcomes such as lower pain thresholds, fatigue, cognitive impairment, depression, and cardiovascular disease…
Abstract Number: 2592 • ACR Convergence 2023
Trends, Sociodemographic and Clinical Factors Associated with Avascular Necrosis and Related Arthroplasties in Hospitalized Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Rashmi Dhital¹, Neha Singh², Brian Pedersen² and Christie M. Bartels³, ¹UC San Diego, San Diego, CA, ²University of California San Diego, San Diego, CA, ³University of Wisconsin, School of Medicine and Public Health, Madison, WI
Background/Purpose: Avascular necrosis (AVN) can be a debilitating complication of autoimmune diseases and steroid treatment, with a higher prevalence in systemic lupus erythematosus (SLE) (0.8-33%)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].